GlassScriptPhysician profile
Tanner John Manwaring
NPI 1275197196
$4,368.53
in general payments reported to CMS, 2019-2025
24 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $916 · 2023: $540 · 2024: $1,273 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.80 | 2021-2025 | |
| Lundbeck LLC | $444.55 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $398.93 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $383.74 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $317.50 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $305.81 | 2024-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $232.29 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $206.40 | 2024-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.24 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $158.28 | 2022-2024 | |
| Tris Pharma INC | $155.51 | 2022-2025 | Dyanavel Xr |
| Alkermes, INC. | $139.88 | 2022-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $132.68 | 2021-2025 | Trintellix |
| Biogen, INC. | $125.32 | 2024-2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $84.87 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $81.17 | 2022-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $44.87 | 2022-2023 | Austedo |
| Bausch Health US, LLC | $39.38 | 2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $37.07 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $35.69 | 2024 | Xelstrym |
| Tempus Ai, INC | $27.64 | 2025 | Tempus Pixel |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2025 | Cobenfy |
| Almatica Pharma LLC | $13.58 | 2023 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Manwaring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.